Notification
No new Notification messages
Enviro Infra Engineers IPO is Open!
Apply for the Enviro Infra Engineers IPO through UPI in just minutes.
Q2 FY'24-25 Results of Top Companies
Reliance, TCS, HDFC Bank & more: Explore key financial highlights from India's top quarterly results.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
divi s laboratories ltd stock

DIVI S LABORATORIES LTD Share Price

6000 22.89 (0.38%)
Nov 22 2024 03:29 PM Pharmaceuticals NSE: DIVISLAB

DIVI S LABORATORIES LTD Share Price Update

As of the latest trading session, DIVI S LABORATORIES LTD share price is currently at 6000, which is up by 22.89 from its previous closing. Today, the stock has fluctuated between 5980.00 and 6056.95. Over the past year, DIVI S LABORATORIES LTD has achieved a return of 62.04 %. In the last month alone, the return has been 3.10 %. Read More...

DIVI S LABORATORIES LTD Performance

Day Range

Low5980.00 High6056.95
5998.35

52 Week Range

Low 3350.00 High 6275.85
5998.35

DIVI S LABORATORIES LTD Share Price

10940

532488

DIVISLAB

img img img img
No Data Available

Open Price

5980.00

Prev. Close

5977.10

Volume (Shares)

309695.00

Total traded value

18576.59

Upper Circuit

6574.80

Lower Circuit

5379.40

Note: The current prices & values are delayed, Login to your account for live updates.

DIVI S LABORATORIES LTD Fundamentals


(Standalone)

Market Cap (Cr) 159281.10
PE Ratio (TTM) 86.70
Book Value / Share 513.62
Beta 0.46
ROE 12.04%
EPS (TTM) 69.20
Dividend Yield 0.50%
Net Profit Qtr (Cr) 518.00

DIVI S LABORATORIES LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 2302.00
Operating Expense 1672.00
Net Profit 518.00
Net Profit Margin (%) 22.50
Earnings Per Share (EPS) 19.51
EBITDA 834.00
Effective Tax Rate (%) 29.52
Particulars JUN 2024 (Values in Cr)
Revenue 2063.00
Operating Expense 1539.00
Net Profit 430.00
Net Profit Margin (%) 20.84
Earnings Per Share (EPS) 16.18
EBITDA 700.00
Effective Tax Rate (%) 28.68
Particulars MAR 2024 (Values in Cr)
Revenue 2259.00
Operating Expense 1638.00
Net Profit 531.00
Net Profit Margin (%) 23.50
Earnings Per Share (EPS) 19.99
EBITDA 796.00
Effective Tax Rate (%) 24.14
Particulars DEC 2023 (Values in Cr)
Revenue 1808.00
Operating Expense 1412.00
Net Profit 358.00
Net Profit Margin (%) 19.80
Earnings Per Share (EPS) 13.50
EBITDA 585.00
Effective Tax Rate (%) 26.93
Particulars SEP 2023 (Values in Cr)
Revenue 1868.00
Operating Expense 1489.00
Net Profit 342.00
Net Profit Margin (%) 18.30
Earnings Per Share (EPS) 12.89
EBITDA 559.00
Effective Tax Rate (%) 26.29
Particulars MAR 2024 (Values in Cr)
Revenue 7665.00
Operating Expense 5870.00
Net Profit 1576.00
Net Profit Margin (%) 20.56
Earnings Per Share (EPS) 59.37
EBITDA 2511.00
Effective Tax Rate (%) 26.07
Particulars MAR 2023 (Values in Cr)
Revenue 7625.00
Operating Expense 5620.00
Net Profit 1808.00
Net Profit Margin (%) 23.71
Earnings Per Share (EPS) 68.11
EBITDA 2697.00
Effective Tax Rate (%) 23.19
Particulars MAR 2022 (Values in Cr)
Revenue 8879.82
Operating Expense 5314.55
Net Profit 2948.54
Net Profit Margin (%) 33.20
Earnings Per Share (EPS) 111.07
EBITDA 3987.72
Effective Tax Rate (%) 19.80
Particulars MAR 2021 (Values in Cr)
Revenue 6798.61
Operating Expense 4233.26
Net Profit 1954.72
Net Profit Margin (%) 28.75
Earnings Per Share (EPS) 73.63
EBITDA 2883.21
Effective Tax Rate (%) 25.61
Particulars MAR 2020 (Values in Cr)
Revenue 5310.57
Operating Expense 3687.14
Net Profit 1372.71
Net Profit Margin (%) 25.84
Earnings Per Share (EPS) 51.71
EBITDA 2005.30
Effective Tax Rate (%) 24.29
Particulars MAR 2024 (Values in Cr)
Book Value / Share 512.11
ROE % 12.15
ROCE % 16.41
Total Debt to Total Equity 0.00
EBITDA Margin 32.44
Particulars MAR 2023 (Values in Cr)
Book Value / Share 481.77
ROE % 14.89
ROCE % 19.31
Total Debt to Total Equity 0.00
EBITDA Margin 34.94
Particulars MAR 2022 (Values in Cr)
Book Value / Share 441.82
ROE % 28.16
ROCE % 34.96
Total Debt to Total Equity 0.00
EBITDA Margin 44.61
Particulars MAR 2021 (Values in Cr)
Book Value / Share 350.15
ROE % 23.90
ROCE % 31.97
Total Debt to Total Equity 0.00
EBITDA Margin 41.95
Particulars MAR 2020 (Values in Cr)
Book Value / Share 275.38
ROE % 19.30
ROCE % 25.29
Total Debt to Total Equity 0.01
EBITDA Margin 37.31
Particulars MAR 2024 (Values in Cr)
Book Value / Share 508.83
ROE % 12.04
ROCE % 16.27
Total Debt to Total Equity 0.00
EBITDA Margin 32.77
Particulars MAR 2023 (Values in Cr)
Book Value / Share 479.43
ROE % 14.82
ROCE % 19.27
Total Debt to Total Equity 0.00
EBITDA Margin 35.38
Particulars MAR 2022 (Values in Cr)
Book Value / Share 440.44
ROE % 28.13
ROCE % 35.01
Total Debt to Total Equity 0.00
EBITDA Margin 44.92
Particulars MAR 2021 (Values in Cr)
Book Value / Share 349.28
ROE % 23.57
ROCE % 31.55
Total Debt to Total Equity 0.00
EBITDA Margin 42.43
Particulars MAR 2020 (Values in Cr)
Book Value / Share 275.63
ROE % 19.21
ROCE % 25.17
Total Debt to Total Equity 0.01
EBITDA Margin 37.78
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 3980.00
Total Assets 15470.00
Total Liabilities 15470.00
Total Equity 13571.00
Share Outstanding 265468580
Price to Book Ratio 6.75
Return on Assets (%) 10.34
Return on Capital (%) 11.79
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 4214.00
Total Assets 14439.00
Total Liabilities 14439.00
Total Equity 12767.00
Share Outstanding 265468580
Price to Book Ratio 5.89
Return on Assets (%) 12.63
Return on Capital (%) 14.29
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2818.88
Total Assets 13374.71
Total Liabilities 13374.71
Total Equity 11728.18
Share Outstanding 265468580
Price to Book Ratio 10.00
Return on Assets (%) 22.13
Return on Capital (%) 25.24
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2156.03
Total Assets 10774.07
Total Liabilities 10774.07
Total Equity 9294.61
Share Outstanding 265468580
Price to Book Ratio 10.39
Return on Assets (%) 18.41
Return on Capital (%) 21.35
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 122.63
Total Assets 8535.70
Total Liabilities 8535.70
Total Equity 7309.92
Share Outstanding 265468580
Price to Book Ratio 7.21
Return on Assets (%) 16.12
Return on Capital (%) 18.74
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 3961.00
Total Assets 15362.00
Total Liabilities 15362.00
Total Equity 13484.00
Share Outstanding 265468580
Price to Book Ratio 6.75
Return on Assets (%) 10.25
Return on Capital (%) 11.69
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 4188.00
Total Assets 14352.00
Total Liabilities 14352.00
Total Equity 12705.00
Share Outstanding 265468580
Price to Book Ratio 5.89
Return on Assets (%) 12.59
Return on Capital (%) 14.23
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2803.68
Total Assets 13307.86
Total Liabilities 13307.86
Total Equity 11691.35
Share Outstanding 265468580
Price to Book Ratio 10.00
Return on Assets (%) 22.15
Return on Capital (%) 25.22
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 2142.01
Total Assets 10723.77
Total Liabilities 10723.77
Total Equity 9271.57
Share Outstanding 265468580
Price to Book Ratio 10.39
Return on Assets (%) 18.22
Return on Capital (%) 21.08
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 107.36
Total Assets 8514.11
Total Liabilities 8514.11
Total Equity 7316.69
Share Outstanding 265468580
Price to Book Ratio 7.21
Return on Assets (%) 16.12
Return on Capital (%) 18.68
Particulars MAR 2024 (Values in Cr)
Net Income 2163.00
Cash from Operations 1637.00
Cash from Investing -269.00
Cash from Financing -799.00
Net change in Cash 193.00
Free Cash Flow 2640.00
Particulars MAR 2023 (Values in Cr)
Net Income 2369.00
Cash from Operations 2932.00
Cash from Investing -2707.00
Cash from Financing -797.00
Net change in Cash -1045.00
Free Cash Flow 3405.00
Particulars MAR 2022 (Values in Cr)
Net Income 3683.50
Cash from Operations 2552.78
Cash from Investing -2194.92
Cash from Financing -532.44
Net change in Cash -815.56
Free Cash Flow 3265.98
Particulars MAR 2021 (Values in Cr)
Net Income 2666.04
Cash from Operations 2591.25
Cash from Investing 75.13
Cash from Financing -34.89
Net change in Cash 1987.17
Free Cash Flow 3501.44
Particulars MAR 2020 (Values in Cr)
Net Income 1819.46
Cash from Operations 1661.17
Cash from Investing -83.47
Cash from Financing -1091.42
Net change in Cash 41.05
Free Cash Flow 2844.38
Particulars MAR 2024 (Values in Cr)
Net Income 2132.00
Cash from Operations 1639.00
Cash from Investing -268.00
Cash from Financing -798.00
Net change in Cash 200.00
Free Cash Flow 2641.00
Particulars MAR 2023 (Values in Cr)
Net Income 2354.00
Cash from Operations 2919.00
Cash from Investing -2707.00
Cash from Financing -796.00
Net change in Cash -1056.00
Free Cash Flow 3391.00
Particulars MAR 2022 (Values in Cr)
Net Income 3676.52
Cash from Operations 2539.95
Cash from Investing -2195.40
Cash from Financing -531.50
Net change in Cash -816.74
Free Cash Flow 3253.62
Particulars MAR 2021 (Values in Cr)
Net Income 2627.87
Cash from Operations 2580.01
Cash from Investing 75.34
Cash from Financing -33.97
Net change in Cash 1988.42
Free Cash Flow 3489.99
Particulars MAR 2020 (Values in Cr)
Net Income 1813.29
Cash from Operations 1654.44
Cash from Investing -81.38
Cash from Financing -1091.25
Net change in Cash 35.84
Free Cash Flow 2837.30
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 55.13 31.68 3.00 422.48 37.54 / 77.70
BLISS GVS PHARMA LTD 131.50 16.46 1.37 1384.72 92.25 / 148.95
CIPLA LTD 1486.30 26.00 4.23 120032.91 1165.10 / 1702.00
FERMENTA BIOTECH LIMITED 326.15 113.25 3.30 959.89 145.00 / 354.60
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 55.13 47.94 9.37 422.48 37.54 / 77.70
AMRUTAJAN HEALTH LTD 697.90 42.45 6.77 2017.67 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6336.90 123.07 23.31 15842.25 4050.15 / 8139.85
BLISS GVS PHARMA LTD 131.50 17.12 1.35 1384.72 92.25 / 148.95

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 5908.90
  • 26 Days 5910.30
  • 10 Days 5901.30
  • 50 Days 5763.40
  • 12 Days 5891.00
  • 100 Days 5404.40
  • 20 Days 5857.10
  • 200 Days 3831.60
5953.90
PIVOT
First Resistance 6027.70
Second Resistance 6078.30
Third Resistance 6152.10
First Support 5903.30
Second Support 5829.50
Third Support 5778.90
RSI 57.62
MACD -19.30
Commodity Channel Index (CCI) 138.71
ADX 34.86
Williams % R -32.86

Over 1 Month

down

3.10

Over 3 Months

down

22.12

Over 6 Months

down

47.79

Over 1 Year

down

62.04

Over 3 Years

down

8.63

Over 5 Years

down

28.18

DIVI S LABORATORIES LTD Future

Future: Price

28 Nov
6014.00
26 Dec
6036.55
30 Jan
6070.35
25 May
0 100 200 300 400 500 600

Discount/Premium

28 Nov
14.00
26 Dec
36.55
30 Jan
70.35
25 May
0 1 2 3 4 5 6 7

Active Calls

6000.0
9765
6100.0
4240
6050.0
3392
25 May
0 500 1000 1500 2000 2500 3000

Active Puts

6000.0
3683
5900.0
2636
5850.0
1732
25 Jul
0 500 1000 1500 2000 2500

DIVI S LABORATORIES LTD Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Others
18.93
Promoter Holdings
51.89
FII
17.25
DII
11.91
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Nilima Prasad Divi Shareholding of Promoter and Promoter Group 5.4E7 20.34
Satchandra Kiran Divi Shareholding of Promoter and Promoter Group 5.4E7 20.34
Life Insurance Corporation Of India Public Shareholding 1.845351E7 6.95
Sbi Mutual Fund Public Shareholding 1.5009924E7 5.65
Swarna Latha Divi Shareholding of Promoter and Promoter Group 1.4E7 5.27
Divi's Biotech Private Limited Shareholding of Promoter and Promoter Group 8000000.0 3.01
Murali Krishna Prasad Divi Shareholding of Promoter and Promoter Group 7567000.0 2.85
Government Of Singapore Public Shareholding 4687501.0 1.77
Government Pension Fund Global Public Shareholding 4074046.0 1.53
Axis Mutual Fund Trustee Limited Public Shareholding 3982663.0 1.5
Nippon Life India Trustee Ltd Public Shareholding 3132323.0 1.18
Madhusudana Rao Divi Shareholding of Promoter and Promoter Group 193090.0 0.07
Radhakrishna Rao Divi Shareholding of Promoter and Promoter Group 0.0 0.0

DIVI S LABORATORIES LTD

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2023-08-11 30.0 Final 2023-08-11 Equity shares 2022-08-11 30.0 Final 2022-08-12 Equity shares 2021-08-17 20.0 Final 2021-08-20 Equity shares 2020-02-25 16.0 Interim 2020-02-26 Equity shares 2019-08-14 16.0 Final 2019-08-17 Equity shares 2018-08-31 10.0 Final 2018-09-04 Equity shares 2017-09-15 10.0 Final 2017-09-19 Equity shares 2016-03-17 10.0 Interim 2016-03-18 Equity shares 2015-08-06 20.0 Final 2015-08-10 Equity shares 2014-07-31 20.0 Final 2014-08-04 Equity shares 2013-07-25 15.0 Final 2013-07-29 Equity shares 2012-07-26 13.0 Final 2012-07-30 Equity shares 2011-06-16 10.0 Final 2011-06-18 Equity shares 2010-07-02 6.0 Final 2010-07-06 Equity shares 2009-06-15 6.0 Final 2009-06-17 Equity shares 2008-06-26 4.0 Final 2008-06-28 Equity shares 2007-03-23 2.0 Interim 2007-03-26 Equity shares 2005-08-11 0.0 Final 2005-08-13 Equity shares
Ex-Date Ex-Bonus Ratio
2015-09-26 2015-09-23 1:1 2009-08-01 2009-07-30 1:1
Ex-Date Old FV NEW FV Record Date
2007-08-03 10.0 2.0 2007-08-10

Divi’s Lab share result highlights

Divi’s Lab’s recent financial results highlight the company’s steady performance in the pharmaceutical sector. The Divi’s Lab share price reacted moderately to the quarterly earnings, which showed a slight increase in revenue. Despite a challenging market environment, the company managed to improve its profit margins through effective cost control measures. EBITDA remained stable, and net profit also saw modest growth, aligning with market expectations. Investors are particularly interested in how Divi’s Lab’s strategic investments and expansion plans will influence future results and the Divi’s Lab share price. Overall, the company’s financial health remains solid, with promising long-term prospects.

Divi’s Lab share annual reports

Divi’s Lab’s annual reports provide a comprehensive overview of the company’s financial stability and strategic goals. Over the past year, the company has shown consistent revenue growth, reflecting its strong position in the industry. The Divi’s Lab share price has mirrored this performance, showing resilience despite broader market volatility. The balance sheet indicates a healthy financial position, supported by strong cash flows and controlled operational costs. The report also outlines the company’s future expansion plans, which are expected to positively impact the Divi’s Lab share price in the coming years.

Divi’s Lab share dividend

Divi’s Lab has maintained a consistent dividend policy, providing shareholders with regular returns. The Divi’s Lab share price often reflects positive sentiment following dividend announcements, as the company is known for its stable financial health. The most recent dividend was modest, in line with its previous years, allowing the company to retain capital for further growth initiatives. Divi’s Lab’s approach to dividend distribution balances rewarding shareholders while ensuring the company’s long-term growth remains on track. Investors continue to monitor future dividends as a key aspect of the company’s financial strategy and its impact on the Divi’s Lab share price.

Divi's Laboratories Limited Overview

Since its inception in 1990, Divis Laboratories Ltd has carved a niche in manufacturing and exporting APIs, intermediates, and Nutraceutical ingredients, catering to the global pharmaceutical and nutraceutical industries. With a portfolio that includes 30 high-volume generic APIs, custom synthesis services for top pharma companies, and a specialised unit for carotenoids in Visakhapatnam, Divis stands out for its extensive range and global reach. The company boasts six multi-purpose manufacturing facilities in Telangana and Visakhapatnam, recognized among the largest API production sites worldwide, with a significant reactor capacity and multiple cGMP and customer quality audits. Offering a diverse product list across various therapeutic categories, Divis Laboratories is a global leader in Naproxen and has a strong international presence with marketing subsidiaries in the USA and Switzerland. The majority of its revenue comes from product sales, heavily weighted towards exports, especially to Europe and North America. Moving forward, Divis is expanding with a new manufacturing site in Kakinada and investing in cutting-edge technologies, underscoring its commitment to innovation and growth in the pharmaceutical sector.

About DIVI S LABORATORIES LTD

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by DIVI S LABORATORIES LTD

Learn More About Stocks

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Additional FAQs

Who is the CEO of Divi’s Lab?

The CEO of Divi’s Lab oversees the company’s strategic operations and long-term vision. Under their leadership, Divi’s Lab has maintained its strong market position, and their decisions play a crucial role in shaping the company’s performance. The CEO’s leadership directly influences the Divi’s Lab share price as they focus on sustaining growth and expanding the company’s global footprint. Investors closely watch the CEO’s direction as it impacts both the company’s performance and its market valuation.

 

When was Divi’s Lab established?

Divi’s Lab was established several decades ago, marking its entry into the pharmaceutical sector with a focus on innovation and research. Since its inception, the company has seen steady growth in both its operations and market value. The establishment of Divi’s Lab set the foundation for its current market success, with the Divi’s Lab share price reflecting its long-standing reputation in the industry. Over the years, the company has consistently expanded, becoming a key player in the pharmaceutical market.

 

What factors influence the Divi’s Lab share price?

Several factors influence the Divi’s Lab share price, including the company’s financial performance, product pipeline, and broader industry trends. Key internal factors such as revenue growth, profitability, and operational efficiency are critical in shaping investor sentiment. External influences like regulatory changes, market conditions, and competitive pressures also play a role. Investors and stakeholders closely monitor these variables to gauge the potential movement of the Divi’s Lab share price, especially in light of evolving market dynamics.

 

Is Divi’s Lab debt free?

Divi’s Lab maintains a relatively low debt level, positioning itself as a financially stable company. While it may have some debt, it is well-managed and does not pose significant risks to the company’s overall performance. This debt strategy helps maintain investor confidence in the company’s future, positively influencing the Divi’s Lab share price. The company’s balance sheet reflects its prudent financial management, allowing it to focus on growth while maintaining a healthy capital structure.

 

How has the Divi’s Lab share price performed over the past year?

The Divi’s Lab share price has experienced moderate fluctuations over the past year, largely influenced by the company’s quarterly results and external market conditions. While the price has seen some downturns, it has also shown resilience, particularly during periods of positive financial performance. Overall, the Divi’s Lab share price has remained stable, reflecting the company’s solid position in the pharmaceutical sector. Investors continue to monitor future performance closely to anticipate potential shifts in the share price.

Frequently Asked Questions

What is the Share Price of Divis Laboratories Ltd?

Answer Field

The share price of Divis Laboratories Ltd for NSE is ₹ 6000 and for BSE is ₹ 5990.35.

What is the Market Cap of Divis Laboratories Ltd?

Answer Field

The market cap of Divis Laboratories Ltd for NSE is ₹ 15,92,81.10 Cr. and for BSE is ₹ 15,90,25.00 Cr. as of now.

What is the 52 Week High and Low of Divis Laboratories Ltd?

Answer Field

The 52 Week High and Low of Divis Laboratories Ltd for NSE is ₹ 6275.85 and ₹ 3350.00 and for BSE is ₹ 6276.20 and ₹ 3350.05.

How to Buy Divis Laboratories Ltd share?

Answer Field

You can trade in Divis Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Divis Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 62.04%.

What is the Current Share Price of Divis Laboratories Ltd?

Answer Field

Divis Laboratories Ltd share price is for NSE ₹ 6000 & for BSE ₹ 5990.35 as on Nov 22 2024 03:29 PM.

What is the Market Cap of Divis Laboratories Ltd Share?

Answer Field

The market cap of Divis Laboratories Ltd for NSE ₹ 15,92,81.10 & for BSE ₹ 15,90,25.00 as on Nov 22 2024 03:29 PM.

What is the P/E Ratio of Divis Laboratories Ltd Share?

Answer Field

As on Nov 22 2024 03:29 PM the price-to-earnings (PE) ratio for Divis Laboratories Ltd share is 86.70.

What is the PB ratio of Divis Laboratories Ltd Share?

Answer Field

As on Nov 22 2024 03:29 PM, the price-to-book (PB) ratio for Divis Laboratories Ltd share is 513.62.

How to Buy Divis Laboratories Ltd Share?

Answer Field

You can trade in Divis Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Divis Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Divis Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Divis Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs + Users

icon-with-text

4.8+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5000+ Cr MTF Book

icon-with-text
loader